Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center. The results, published in Cancer Discovery, prime the combination strategy for future clinical trials.
👉 Full Story

Woman Gets Naked and SCREAMS on Southwest flight to Phoenix
- The Companion Review - Jacques van Zyl
- Joy Reid is Ready to Burn MSNBC's House Down
- TikTok's New Artist Account: A Revolution in Music Discovery - Bertha Stephens
- Trump Struck a Blow for Gun Rights in 2024. Now We Must Make That Victory Permanent. - Bronson Winslow
- ‘That’s Absurd’: Karoline Leavitt Lights Into ‘Low-Level Judges’ Blocking Bureaucrat Firings - Harold Hutchison
- Signs and Symptoms of Thrush (Oral Candidiasis) - Sarah Jividen, RN

Nothing Budget Phones: Worth the Hype? ft. Phone 3A
- The Engadget team's favorite productivity tools to get things done - Engadget
- How to Evaluate Your Budget and Take Control of Your Spending - Zoul
- Moonvalley’s Marey is a state-of-the-art AI video model trained on FULLY LICENSED data - Carl Franzen
- The Future of Energy Efficiency: Windows 11 Testing Energy Saver Mode for Laptops and Desktops - Michael A. Medeiros
- ChatGPT Experiences Outage Amid OpenAI's Internal Turmoil - Michael Terry
- How to get your grill ready for the outdoor season - Billy Steele